Intralesional interleukin-2: A novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma.

Langan, Ewan A; Kümpers, Christiane; Graetz, Victoria; Perner, Sven; Zillikens, Detlef; Terheyden, Patrick

Langan, Ewan A; Kümpers, Christiane; Graetz, Victoria; Perner, Sven; Zillikens, Detlef; Terheyden, Patrick.

Afiliação

Langan EA; Department of Dermatology, University of Luebeck, Lubeck, Germany.
Kümpers C; Department of Dermatological Science, University of Manchester, Manchester, United Kingdom.
Graetz V; Department of Pathology of the University Hospital Schleswig-Holstein, Campus Luebeck and the Research Center Borstel, Leibniz Lung Center, Luebeck and Borstel, Lubeck, Germany.
Perner S; Department of Dermatology, University of Luebeck, Lubeck, Germany.
Zillikens D; Department of Pathology of the University Hospital Schleswig-Holstein, Campus Luebeck and the Research Center Borstel, Leibniz Lung Center, Luebeck and Borstel, Lubeck, Germany.
Terheyden P; Department of Dermatology, University of Luebeck, Lubeck, Germany.

Dermatol Ther ; 32(3): e12901, 2019 05.

Article em En | MEDLINE | ID: mdl-30974014

Assuntos

Interleucina-2/administração & dosagem; Melanoma/tratamento farmacológico; Receptor de Morte Celular Programada 1/antagonistas & inibidores; Idoso; Antígeno B7-H1/análise; Humanos; Injeções Intralesionais; Masculino; Melanoma/secundário; Pessoa de Meia-Idade

Palavras-chave

PD-L1; checkpoint inhibitors; interleukin 2; melanoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Pele Base de dados: MEDLINE Assunto principal: Interleucina-2 / Receptor de Morte Celular Programada 1 / Melanoma Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Dermatol Ther Assunto da revista: DERMATOLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google